BETA

IPO registrations (S-1, F-1) · Registrants

SANGAMO THERAPEUTICS, INC

SEC CIK
1001233 · filings on EDGAR ↗
Name on the registration
SANGAMO BIOSCIENCES INC
Former names
SANGAMO BIOSCIENCES INC (2000–2017)
Registration
Form S-1, first filed 2000-02-11, last 2000-04-06; 1 initial registration, 6 amendments
Outcome
Withdrawal requested 2001-09-26
Industry (SIC)
Biological Products, (No Diagnostic Substances) 2836
Incorporated in
DE
Business address
501 CANAL BLVD., Richmond, CA 94084
EIN
68-0359556
Ticker
SGMOQ
EDGAR entity type
operating
Insiders and CEO pay
SANGAMO THERAPEUTICS, INC on the corporate pages

Offering terms

Shares offered
3,500,000
Listing
Nasdaq under the symbol SGMO
Lead underwriters
Lehman Brothers (1,541,500 shares); ING; William Blair (154,000 shares); J.P. Morgan (694,000 shares); ING Barings LLC (694,000 shares); Services Corp (49,000 shares)
Syndicate
Hambrecht & Quist; CIBC World Markets (49,000); Merrill Lynch (49,000); Citigroup (49,000); Cowen (49,000); UBS (49,000); RBC Capital Markets (24,500); Edward D. Jones & Co., L.P (24,500); Legg Mason (24,500); Raymond James (24,500); Wachovia (24,500)

Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.

Filings 8

FiledFormWhat it isName as filedEDGAR
2000-02-11S-1S-1 (registration)SANGAMO BIOSCIENCES INC0000950149-00-000209 ↗
2000-02-24S-1/AS-1/A (amendment)SANGAMO BIOSCIENCES INC0000950149-00-000384 ↗
2000-03-14S-1/AS-1/A (amendment)SANGAMO BIOSCIENCES INC0000950149-00-000518 ↗
2000-04-04S-1/AS-1/A (amendment)SANGAMO BIOSCIENCES INC0000950149-00-000763 ↗
2000-04-05S-1/AS-1/A (amendment)SANGAMO BIOSCIENCES INC0000950149-00-000765 ↗
2000-04-05S-1/AS-1/A (amendment)SANGAMO BIOSCIENCES INC0000950149-00-000773 ↗
2000-04-06S-1/AS-1/A (amendment)SANGAMO BIOSCIENCES INC0000950149-00-000783 ↗
2001-09-26RWRW (withdrawal request)SANGAMO BIOSCIENCES INC0000912057-01-533426 ↗

Prospectus pages read 1

FiledFormRead asRangePriceSharesProceedsListingUnderwritersWhat was foundDocument
2000-04-06S-1/Aregistration statement$15.003,500,000$52,500,000Nasdaq SGMO17from the submission text; price sentence, shares headline, proceeds table, underwriting table 15, cover names 4document ↗

Officers, directors and large holders Forms 3, 4 and 5

InsiderRoleTitleFilingsYearsOn this site
LANPHIER EDWARD O IIDirector; Director,Officer; Director,Officer,TenPercentOwnerPres and Chief Ex Officer; Pres & Chief Ex Officer; President & CEO; President & Chief Exec Officer802006–2017
ZANTE GREGOfficerSr. Director Finance & Admin; Vice President, Fin. & Admin.; VP, Finance & Administration102006–2008
Gregory Philip DOfficerCSO & Vice President, Research; See Remarks; Sr. VP Res. & CSO; SVP of Research & CSO; SVP, Research & CSO; Vice President, Research; Vice President, Research & CSO; VP, Therapeutic Dev. & CMO652006–2015
GERBER WILLIAM GDirector112006–2010
LARSON JOHN WILLIAMDirector292006–2015person page Fuzzy
Liu MargaretDirector32006–2008
Mento Steven JDirector242006–2018
Wolff Henry WardDirector; OfficerExecutive VP and CFO; Exec VP & CFO; Exe VP & CFO582006–2016
WOOD MICHAEL CDirector32006–2008
ANDO DALE GOfficerVP, Therapeutic Dev. & CMO472006–2015
Ichikawa David GOfficerSenior VP, Bus. Dev.142006–2011
Kopp LeRoy CTenPercentOwner42007
WIGGANS THOMAS GDirector52008–2011
Cleveland Paul BDirector182008–2016
DILLY STEPHEN GEORGEDirector152010–2020
RINGO WILLIAM RDirector192010–2017person page Fuzzy
NICHOL GEOFFREYOfficerExecutive Vice President, R&D82011–2015
Ramasastry SairaDirector202012–2022
PARKER H STEWARTDirector182014–2025
Kolchinsky PeterOther; TenPercentOwner102015
RA Capital Healthcare Fund LPOther; TenPercentOwner102015
RA CAPITAL MANAGEMENT, LLCOther; TenPercentOwner102015
Macrae SandyDirector,Officer; OfficerPresident and CEO; President, CEO and Director; PRESIDENT, CEO AND DIRECTOR322016–2026
Carey RobertDirector122016–2025
Conner Edward R.OfficerSenior VP & CMO; Sr. VP & Chief Medical Officer182016–2019
Herberts Curt A. IIIOfficerSenior VP & CBO; Sr.VP & Chief Business Officer192016–2018
Yi KathyOfficerEVP & Chief Financial Officer; Senior VP & CFO; SVP & Chief Financial Officer202017–2019
JEFFS ROGERDirector42017–2018
Zakrzewski Joseph SDirector102017–2022
Turner Heather DOfficerEVP, General Counsel & Sec.; SVP and General Counsel32018–2019
Smith Karen L.Director102018–2025
Boissel StephaneOfficerEVP, Corporate Strategy; EVP, Corp. Strategy; EVP, Corp. Strat. & Int. CFO92018–2020
Woolfson AdrianOfficerEVP, Research and Development; EVP Research & Development42019–2020
Duraibabu PrathyushaOfficerPRINCIPAL FINANCIAL OFFICER; SVP, CFO, PFO and PAO; SVP, Chief Financial Officer; SVP, CHIEF FINANCIAL OFFICER; Vice President, Finance; VP, PFO and PAO; VP Principal Acct. Officer; VP, Principal Acct. Officer372019–2026
LOEB GARYOfficerEVP & General Counsel; EVP, General Counsel & Sec.62019–2021
Ramelmeier Rolf AndrewOfficerEVP, Technical Operations82019–2023
Lee SungOfficerEVP, Chief Financial Officer42019–2020
Meyers James RDirector92019–2025
Markels JohnDirector82020–2025
BIOGEN INC.TenPercentOwner92020–2023
Biogen MA Inc.TenPercentOwner92020–2023
McClung David MarkOfficerEVP Chief Business Officer; EVP, Chief Business Officer; EVP, Chief Operating Officer112020–2023
Hillan Kenneth J.Director72020–2025
Schott Robert J.OfficerSVP, Head of Development42021–2022
Fontenot Jason D.OfficerSVP, Chief Scientific Officer82021–2023person page Fuzzy
Willoughby Scott B.OfficerSVP, CHIEF LEGAL OFFICER, SECY; SVP, Gen. Counsel & Secretary; SVP, GEN. COUNSEL & SECRETARY312021–2026
Dubois-Stringfellow NathalieOfficerSVP-Chief Development Officer; SVP-CHIEF DEVELOPMENT OFFICER232022–2026
Beers CourtneyDirector52022–2025
Horn Margaret ADirector52022–2025
Pooler AmyOfficerVP, Head of Research; VP, HEAD OF RESEARCH62023–2024
Davis Gregory DOfficerHead of Research & Technology152024–2026
Jain NikunjOfficerPrincipal Accounting Officer72025–2026

Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.

Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.

Also on this site Fuzzy

RecordName as filedWhereDatasetMatched by
Lobbying clientSANGAMO THERAPEUTICS, INCCAFederal lobbying (LDA)name and state
Patent assigneeSANGAMO THERAPEUTICS, INC.CAPatents (USPTO)name and state
SEC filerSANGAMO THERAPEUTICS, INCSEC filers (EDGAR)CIK (EXACT)
Trademark ownerSangamo Therapeutics, Inc.CATrademarks (USPTO)name and state
Form 5500 plan sponsorSANGAMO THERAPEUTICS, INC.EIN (EXACT)
Person pageJason D FontenotPeople (Form 990 officers, directors and employees)officer, director or 10% owner on the company's Forms 3, 4 and 5 (Officer)
Person pageJohn William LarsonPeople (Form 990 officers, directors and employees)officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director)
Person pageWilliam R RingoPeople (Form 990 officers, directors and employees)officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director)

Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.

Others with the same interests

SIC industry Biological Products, (No Diagnostic Substances), CA first:

More with this interest.

In other datasets, the same topic (Health) in CA:

Interests: Biological Products, (No Diagnostic Substances) · Health